Edition:
United States

bluebird bio Inc (BLUE.O)

BLUE.O on Nasdaq

119.68USD
19 Jun 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$119.68
Open
--
Day's High
--
Day's Low
--
Volume
436
Avg. Vol
503,594
52-wk High
$189.31
52-wk Low
$87.49

About

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical... (more)

Overall

Beta: 2.03
Market Cap(Mil.): $5,824.04
Shares Outstanding(Mil.): 45.59
Dividend: --
Yield (%): --

Financials

  BLUE.O Industry Sector
P/E (TTM): -- 69.29 32.55
EPS (TTM): -7.36 -- --
ROI: -25.26 8.90 13.82
ROE: -29.40 10.04 15.24

Bluebird prices gene therapy at 1.58 million euros over 5 years

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

Jun 14 2019

UPDATE 1-Bluebird prices gene therapy at 1.58 mln euros over 5 years

June 14 Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder. The company proposed an installment plan, with 315,000 euros paid up front and four additional annual payments due only if the treatment continues to be effective.

Jun 14 2019

Bluebird prices gene therapy at 1.575 mln euros over five years

June 14 Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.575 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

Jun 14 2019

EMA panel recommends approval of Bluebird Bio's first gene therapy

A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.

Mar 29 2019

UPDATE 1-EMA panel recommends approval of Bluebird Bio's first gene therapy

March 29 A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.

Mar 29 2019

EMA panel recommends approval of Bluebird Bio's first gene therapy

March 29 A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.

Mar 29 2019

Earnings vs. Estimates